Palbociclib + cetuximab versus cetuximab in patients with <i>CDKN2A</i>-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial.Jessica Ley, Douglas R. Adkins, Jared Cohen et al.|Journal of Clinical Oncology|2023Cited by 5
Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 TrialWade L. Thorstad, D. Adkins, Jason T. Rich et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 5